Alnylam Pharmaceuticals Inc (ALNY) FY2025Q2 Earning Prediction

07/31 04:00:00

Pre-Market

Alnylam Pharmaceuticals Inc (ALNY) is set to release its FY2025Q2 earnings performance on 07/31 04:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 662.45M and an earnings per share (EPS) of 0.16 for the FY2025Q2. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!

Estimate

Actual

Surprise

RevenueBEAT

662.45M

773.69M

+16.79%

EPSBEAT

0.16

0.32

+100.00%

AI Earnings Prediction

Prediction for FY2025Q2

Earnings Date: Jul 31, 2025

The earnings forecast predicts a strong beat, driven by robust AMVUTTRA sales and favorable market conditions.

Strong Beat

Last 0 quarters:

4 beats1 misses

Scenario Analysis

The AI analyzes the probability of each scenario occurring and identifies the triggering conditions.

Scenario

Prob.

Stock Reaction

Trigger Condition

Strong Beat

55%

+8-12%

AMVUTTRA U.S./EU sales materially beat IQVIA estimates.

Beat

30%

+3-5%

Solid TTR growth but collaboration/margin drag.

Neutral

10%

Flat

AMVUTTRA sales in line; rare disease growth stalls.

Miss

-5-7%

IQVIA data overstates actual demand.

Unlock Free Scenario Probability

Key Indicators Forecast

The AI provides itemized forecasts for key indicators, potentially including revenue, EPS, gross margin, and free cash flow.

Revenue

EPS

Currency:

No data

Actual

Estimate

Metric

Prediction

Justification

Revenue

Strong Beat

AMVUTTRA’s ATTR-CM launch momentum and EC approval drive TTR franchise growth beyond consensus.

EPS

Beat

Revenue upside likely offsets royalty/margin pressures; no explicit expense warnings in Fact Data.

Unlock Free Key Indicators Forecast

Prediction Logic & Rational

Fact Data Analysis:

TTR Franchise Momentum:

AMVUTTRA’s U.S. launch in ATTR-CM (approved March 2025) is exceeding expectations, with BofA’s survey indicating ~~195 scripts since launch (~~50% new patients) and projected 29% peak share. Analysts (Jefferies, JPMorgan, Citi) highlight upward revisions to Amvuttra forecasts based on IQVIA sales data tracking.
EC approval for AMVUTTRA in cardiomyopathy (June 2025) opens a large European market, supporting accelerated adoption.

Rare Disease Franchise Growth:

OXLUMO reimbursement in Canada (July 2025) removes access barriers, likely boosting patient growth.
HELIOS-B Phase 3 data presentation (May 2025) reinforces prescriber confidence in AMVUTTRA’s efficacy, indirectly supporting GIVLAARI/OXLUMO adoption.

Collaboration Revenue Uncertainty:

No new milestone or partnership announcements in Fact Data; consensus likely already models low collaboration revenue.

Margin & Expense Management:

Higher-than-expected AMVUTTRA sales volume could offset escalating royalty costs.

Prediction Logic & Rational

Tactical Strategy Recommendations

Near-Term Plays:

Bull Call Spread: Buy August $340 calls / Sell $360 calls to capitalize on upside while limiting premium costs.
Stock Accumulation: Strong institutional sentiment (analyst PTs up 15-25% in 3 months) supports momentum.

Catalyst Hedge:

Long-term puts (Jan 2026 $300) to guard against rare disease execution risks.

Rationale: High likelihood of Strong Beat driven by AMVUTTRA’s outperformance, priced into bullish options flow but not fully reflected in consensus revenue revisions.

Tactical Strategy Recommendations

Earnings Surprise Analysis

The chart displays the extent of earnings surprises and corresponding stock price movements for each earnings event.

Revenue

EPS

ALNY Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Neutral11-19

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript

Neutral11-10

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript

Positive10-30

The earnings call summary and Q&A indicate strong financial performance and optimistic guidance, particularly with increased revenue guidance and global expansion. The management's confidence in product launches and pipeline development, alongside positive reception from payers and no significant barriers, suggest a positive outlook. Although some uncertainties exist, such as CMS reimbursement changes, the overall sentiment remains positive with growth prospects in multiple areas.

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Neutral9-10

ALNY Slides

Alnylam Q2 2025 slides: ATTR-CM launch drives 64% revenue growth, guidance raised

2025-07-31

ALNY Report

ALNYLAM PHARMACEUTICALS, INC. 10-K

10-K

2025-02-13

ALNYLAM PHARMACEUTICALS, INC. 10-Q

10-Q

2024-10-31

ALNYLAM PHARMACEUTICALS, INC. 10-Q

10-Q

2024-08-01

ALNYLAM PHARMACEUTICALS, INC. 10-Q

10-Q

2024-05-02

Frequently Asked Questions

What is the Alnylam Pharmaceuticals Inc FY2025Q2 Earnings Release Date and Time?

Alnylam Pharmaceuticals Inc (ALNY) is scheduled to release its FY2025Q2 earnings report onJul 31, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.

What Are the Consensus Forecasts for Alnylam Pharmaceuticals Inc FY2025Q2 Revenue and EPS?

Analysts' consensus predicts 662.45M in revenue and an EPS of 0.16 for Alnylam Pharmaceuticals Inc's FY2025Q2.

What Does Intellectia's AI Predict for Alnylam Pharmaceuticals Inc FY2025Q2 Earnings?

Intellectia's exclusive AI algorithms forecast a Strong Beat forAlnylam Pharmaceuticals Inc's FY2025Q2 earnings, with a prediction date of Jul 31, 2025. Alnylam Pharmaceuticals Inc The earnings forecast predicts a strong beat, driven by robust AMVUTTRA sales and favorable market conditions.

How Can I Use This Earnings Prediction to Trade ALNY Stock?

Leverage Intellectia's AI forecast to position trades ahead of theJul 31, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.

How Accurate Is Intellectia's AI for Earnings Predictions Like Alnylam Pharmaceuticals Inc FY2025Q2?

Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.

How does AI Earnings Prediction generate its forecasts?

AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!

When are the predictions available, and how often are they updated?

Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.

Can I use AI Earnings Prediction for all types of stocks?

Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!